Drug Trial Radar · NCT04966702
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48,145
Actual
Start
Mar 17, 2022
Primary completion
Apr 15, 2024
Study completion Oct 3, 2024
Sponsor
- Lead sponsor
- Barcelona Institute for Global HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- UNITAID
- First posted
- Jul 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 week, up to 99 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The BOHEMIA program consists of a combination of studies organized around a central community prevention mass drug administration protocol and four sub-studies (i.e.; social science, entomology, health economics, and environmental), each written as an individual protocol. The protocol is central but used in two separate, individually powered trials in Mozambique and Kenya. The trials have been powered on the efficacy outcome and designed to meet the requirements of World Health Organization's (WHO) preferred product characteristics (PPC) for endectocides.
Conditions
- Malaria
Interventions
Albendazole PillDrug
Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
Ivermectin PillDrug
Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
Ivermectin Injectable ProductDrug
Veterinary ivermectin injectable will be given to livestock in the relevant cluster
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety (in humans) and efficacy of ivermectin MDA, administered to humans, or humans and livestock simultaneously (only in Mozambique) for the prevention of malaria.Time frame: 6 months
- To determine the safety (in humans) and efficacy of ivermectin MDA, administered to humans, or humans and livestock simultaneously (only in Mozambique) for the prevention of malaria.Time frame: 6 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
KEMRI
Kwale, Kenya
CISM
Mopeia, Zambezia Province, Mozambique
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.